Predose Cannabinoid Findings Complicated the CBD Study’s Washout
Low cannabinoid concentrations sometimes appeared before a new dosing session. The researchers treated those findings as a reason to reconsider washout duration rather than assume that every session began at an analytical zero.
The baseline was measured
The urinary pharmacokinetic study used repeated dosing sessions in eighteen adults. Its limitations section identified low CBD and/or THC-COOH concentrations at baseline between successive sessions. The authors suggested that previously administered material might not have been completely eliminated and that longer washout could be needed in future work.
A predose finding is not self-explanatory
The possibility of residual excretion should be retained, but it does not establish the source of every baseline detection with certainty. Nor does it prove that participants used cannabis outside the protocol. The actual baseline, prior session and specimen history are necessary to evaluate carryover between conditions.
Why a zero assumption can mislead
A later low result may reflect contributions already present before the current dose. Ignoring that starting point can overattribute the entire signal to a new administration. Conversely, baseline trace findings do not erase all postdose patterns. The appropriate interpretation distinguishes background from changes after dosing and avoids treating a washout suggestion as a universal abstinence deadline or an impairment rule.
Related analysis: the urinary CBD route comparison.
Research cited
Sholler and colleagues (2021). Urinary Pharmacokinetic Profile of Cannabidiol, THC and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration. DOI: 10.1093/jat/bkab059.
